European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis

European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis
The European Union has approved Amgen's Amgevita, a biosimilar to Humira (adalimumab), as a treatment for inflammatory bowel diseases (IBDs) such as Crohn's and ulcerative colitis. The European Commission decision applies to moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis in adults, and moderate-to-severe Crohn's in children at least 6 years old. Amgevita can also be used to treat several conditions besides inflammatory IBDs in adults and children, the EU added. The commission approved its use in adults with moderate-to-severe rheumatoid arthritis, psoriatic arthriti, severe active ankylosing spondylitis (AS), severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe chronic plaque psor
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *